Humasis휴마시스

Humasis is still loss-making with revenue recovering, and its shares have fallen sharply over the past year.

Humasis makes point-of-care diagnostic tests and related medical products, plus condoms and an entertainment business through a subsidiary. For the twelve months to H1 2026 it reported revenue of ₩31.7B, an operating loss of ₩10.7B and a net loss of ₩15.6B. The shares closed at ₩2,605 on 20 October 2026, down 59.4% over one year, with a market value of ₩64.3B.

What stands out

• Revenue rose 18.5% in 2025 to ₩30.1B, after a sharp drop in 2023, but operating losses have stayed around ₩10.5B a year.
• Trailing operating margin is -33.8% and net margin is -49.2%, so the business is not yet profitable.
• Cash of ₩63.3B exceeds borrowings of ₩12.6B, and free cash flow over the trailing period was positive at ₩12.7B.
• The shares are up 29.3% over three months but down 4.1% over one month, and the 52-week low in the data is ₩0, which looks like a data gap.
• The DCF fair value model gives a base of ₩4,010 against the ₩2,605 close, but this is a model output rather than an analyst target.
• Recent filings are mostly shareholder meeting notices and holding reports, and the news list is empty in the data.

What to watch

• The shareholders' meeting notices and amendments filed in October 2026, including the agenda once final.
• Whether operating losses narrow relative to revenue in the next reported results, since the trailing operating margin is still deeply negative.
• Foreign ownership is 0% and foreign flows were negative over 20 days, so watch for changes in investor interest; the data does not explain the drivers of the one-year share price fall.